Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

15.0%

3 terminated/withdrawn out of 20 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(38.5%)
Phase 2
5(38.5%)
N/A
3(23.1%)
13Total
Phase 1(5)
Phase 2(5)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT04742751Phase 2Active Not Recruiting

An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer

Role: collaborator

NCT00760656Recruiting

Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer

Role: collaborator

NCT05057702Not ApplicableRecruiting

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Role: collaborator

NCT02868268Active Not Recruiting

Neuroblastoma Precision Trial

Role: collaborator

NCT06946680Phase 1Active Not Recruiting

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)

Role: collaborator

NCT02425904Phase 2Active Not Recruiting

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Role: collaborator

NCT06182163Not ApplicableCompleted

Reduce Sedentary Time in Acute Lymphoblastic Leukemia

Role: collaborator

NCT04995003Phase 1Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Role: collaborator

NCT03971799Phase 1Active Not Recruiting

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT02457845Phase 1Completed

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Role: collaborator

NCT02098512Phase 1Unknown

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Role: collaborator

NCT04773197Not ApplicableTerminated

Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Role: collaborator

NCT02747576Completed

Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma

Role: collaborator

NCT03468075Phase 2Terminated

Gemcitabine Plus Ascorbate for Sarcoma in Adults

Role: collaborator

NCT02926612Unknown

Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection

Role: collaborator

NCT01701492Completed

Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

Role: collaborator

NCT02974569Completed

Improving Symptom Self-management in Adolescents & Young Adults With Cancer

Role: collaborator

NCT01385787Completed

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

Role: collaborator

NCT01772953Phase 2Completed

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Role: collaborator

NCT02338050Phase 2Terminated

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

All 20 trials loaded